Phase I Study of Anti-CD3 x Anti-Her2 Bispecific Antibody in Metastatic Castrate Resistant Prostate Cancer Patients

Background. New nontoxic targeted approaches are needed for patients with castrate resistant prostate cancer (CRPC). Our preclinical studies show that activated T cells (ATC) armed with anti-CD3 x anti-Her2 bispecific antibody (Her2Bi) kill prostate cancer cells lines, induce a Th(1) cytokine patter...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Prostate Cancer
Auteurs principaux: Vaishampayan, Ulka, Thakur, Archana, Rathore, Ritesh, Kouttab, Nicola, Lum, Lawrence G.
Format: Artigo
Langue:Inglês
Publié: Hindawi Publishing Corporation 2015
Sujets:
Clinical Study
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4352947/
https://ncbi.nlm.nih.gov/pubmed/25802762
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2015/285193
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires